← Kalshi

FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)

Openone winner

FDA decision on Anitocabtagene Autoleucel (anito-cel) in 2026

Selected outcome

a full approval or an accelerated approval

90%

a full approval or an accelerated approval · 90%

Stored quote · checking the venue

Scheduled end
Dec 31, 2026 ET
Resolution source
AppliedXL (opens in a new tab)

Price

a full approval or an accelerated approval

Loading price history.

Markets

Event statistics
24h vol
~$0
Volume
~$3,690
Liquidity
—
Open int.
1,304 contracts

How this resolves

One winner.

Scheduled end
Dec 31, 2026 ET
  1. Trading
  2. Closed
  3. In review
  4. Resolved

View on Kalshi